ArticleInternational journal of cancer2016
Treatment to sustain a Th17-type phenotype to prevent skewing toward Treg and to limit premalignant lesion progression to cancer.
Article in International journal of cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 30 citations in OpenAlex.
- Signaling pathways and targeted interventions for precancers.Signal transduction and targeted therapy · 2026Review
- Immunological balance skewing Th1,Th17 towards Th2,Treg in OSCC of hamster induced by 7,12- dimethylbenz[a]anthracene.BMC oral health · 2025Article
- The upregulation of VGF enhances the progression of oral squamous carcinoma.Cancer cell international · 2024Article
- The Role of IL-17 in the Pathogenesis of Oral Squamous Cell Carcinoma.International journal of molecular sciences · 2023Review
- Dynamic changes of exhaustion features in T cells during oral carcinogenesis.Cell proliferation · 2022Article
- Multifaceted functions of chronic inflammation in regulating tumor dormancy and relapse.Seminars in cancer biology · 2022Review
- Low IL-23 levels in peripheral blood and bone marrow at diagnosis of acute leukemia in children increased with the elimination of leukemic burden.Journal of cellular and molecular medicine · 2021Article
- Treg: A Promising Immunotherapeutic Target in Oral Diseases.Frontiers in immunology · 2021Review
- In vivo anti-V-ATPase antibody treatment delays ovarian tumor growth by increasing antitumor immune responses.Molecular oncology · 2020Article
- The Molecular Landscape and Biological Alterations Induced by PRAS40-Knockout in Head and Neck Squamous Cell Carcinoma.Frontiers in oncology · 2020Article
- Th17 response in patients with cervical cancer.Oncology letters · 2018Review
- Interleukin (IL)-12 and IL-23 and Their Conflicting Roles in Cancer.Cold Spring Harbor perspectives in biology · 2018Review
- IL23 and TGF-ß diminish macrophage associated metastasis in pancreatic carcinoma.Scientific reports · 2018Article
- Viral Modulation of TLRs and Cytokines and the Related Immunotherapies for HPV-Associated Cancers.Journal of immunology research · 2018Review
- Article
- HNSCC subverts PBMCs to secrete soluble products that promote tumor cell proliferation.Oncotarget · 2017Article
- Local Immune Responsiveness of Mice Bearing Premalignant Oral Lesions to PD-1 Antibody Treatment.Cancers · 2017Article
- Redirecting the focus of cancer immunotherapy to premalignant conditions.Cancer letters · 2017Review
- Th17 Cells in Protection from Tumor or Promotion of Tumor Progression.Journal of clinical & cellular immunology · 2016Article
- Immunomodulatory role of bitter melon extract in inhibition of head and neck squamous cell carcinoma growth.Oncotarget · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
While immune suppression is a hallmark of head and neck squamous cell carcinoma (HSNCC), the immunological impact of premalignant oral lesions, which often precedes development of HNSCC, is unknown. The present study assessed the changes in splenic and draining lymph node CD4(+) cell populations and their production of select cytokines that occur in mice with carcinogen-induced premalignant oral lesions and the changes that occur as lesions progress to oral cancer. These studies found skewing toward Th1 and Th17-type phenotypes in the spleen and lymph nodes of mice with premalignant oral lesions and a shift to Treg as lesions progress to cancer. Since the role of Th17 cells in the progression from premalignant lesions to cancer is not clear, studies determined the immunological and clinical effect of treating mice bearing premalignant oral lesions with a TGF-β type 1 receptor inhibitor plus IL-23 as an approach to sustain the Th17 phenotype. These studies showed that the treatment approach not only sustained the Th17 phenotype, but also increased distal spleen cell and regional lymph node cell production of other stimulatory/inflammatory mediators and slowed premalignant lesion progression to cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.